[A new psychotropic drug: carpipramine, intermediate compound between 2 therapeutic classes].

An open clinical study was conducted with carpipramine in 100 hospitalized subjects presenting various mental disorders. The therapeutic results on symptoms were assessed both as a whole and with the help of a rating scale. Doses varied from 50 to 400 mg per day. Carpipramine seems to be particularly efficient on schizophrenias, 66 cases of which were tested. The best results were observed in hebephrenic forms and depressive syndroms during the illness; in these indications, carpipramine exerts a clear psychomotor stimulating activity which is useful in decreasing indifference, apathy and ideomotor slowness. Schizophrenias with paranoid delusions or depersonalization anxiety tend to be somehow aggravated. Carpipramine does not seem to be a true antidepressant despite its desinhibitory properties. The compound proves useful in deficits of the psychomotor tone such as those occuring in psychasthenia or the deficit syndrom which follows withdrawal from opiates. Clinical and biological tolerances seem to be excellent and extrapyramidal side effects are exceptional. Carpipramine may be considered as a strongly desinhibitory neuroleptic agent which bears some resemblance to antidepressants because of its psychoanaleptic effect. The authors raise the question of possible antipsychotic properties in higher doses in relation to pharmacological data and a bipolar, antipsychotic and predominantly desinhibitory, therapeutic action.
AuthorsP Deniker, H Lôo, E Zarifian, G Verdeaux, G Garreau
JournalL'Encéphale (Encephale) Vol. 3 Issue 2 Pg. 133-48 ( 1977) ISSN: 0013-7006 [Print] FRANCE
Vernacular TitleUn nouveau médicament psychotrope: la carpipramine, composé de transition entre deux classes thérapeutiques.
PMID19231 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Anti-Anxiety Agents
  • Benzodiazepines
  • Anti-Anxiety Agents (therapeutic use)
  • Benzodiazepines
  • Brief Psychiatric Rating Scale
  • Clinical Trials as Topic
  • Depression (drug therapy)
  • Drug Evaluation
  • Humans
  • Mental Disorders (drug therapy)
  • Neurotic Disorders (drug therapy)
  • Schizophrenia (drug therapy)
  • Substance-Related Disorders (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: